Stock nosedives for cardiovascular drugmaker Arca following Phase IIb AF failure
A small biopharma near Denver is watching its stock plunge following news that its Phase IIb heart drug was a bit of a bust. The …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.